Cagent Vascular

13 articles about Cagent Vascular

• Cagent Vascular Raises $30 Million Series C Financing

  2/20/2024

  Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, announced a Series C Financing close in excess of $30M. U.S. Venture Partners, led the round.

• Cagent Vascular announces initial RECOIL Study results: Serranator demonstrates 49% less recoil than POBA in BTK arteries

  7/11/2023

  Cagent Vascular, the exclusive developer of serration technology for vessel dilatation in endovascular interventions, announced the results of its Below-the-Knee RECOIL study.

• Cagent Vascular announces superior lumen gain, greater volumetric blood flow using Serration Angioplasty: A sub-analysis of the PRELUDE BTK study

  1/31/2023

  Cagent Vascular, the exclusive developer of Serration Angioplasty (Serranator®), announced the results of a comparative sub-analysis of the PRELUDE-Below-the-Knee (BTK) study versus Plain Old Balloon Angioplasty (POBA).

• Cagent Vascular Announces Commercial Launch of the Serranator Above-the-Knee (ATK) Product

  6/1/2022

  Cagent Vascular Inc., a developer of next generation angioplasty balloons using serration technology, announced the expansion of its product offering to include larger balloons to treat superficial femoral and popliteal arteries in the Above-the-Knee (ATK) segment.

• Sectoral Asset Management Makes $9M Investment into Cagent Vascular

  6/17/2021

  Cagent Vascular Inc. 1 , a developer of next generation angioplasty balloons using proprietary serration technology, announced the investment of $9M by Sectoral Asset Management.

• Cagent Vascular Announces FDA 510(k) Clearance for its Serranator Device for the Infrapopliteal Indication and Completion of its PRELUDE-BTK Clinical Trial Enrollment

  4/23/2020

  Cagent Vascular, a developer of serration technology for vessel dilatation in cardiovascular disease interventions, announces FDA 510(k) Clearance of its Serranator® PTA Serration Balloon Catheter for treating below-the-knee (BTK) lesions.

• Cagent Vascular Initiates Enrollment of PRELUDE-BTK Study Using Serranator Device

  1/7/2020

  Cagent Vascular, a developer of serration technology for vessel dilatation in cardiovascular disease interventions, announces the initiation of the PRELUDE-BTK Study

• Cagent Vascular Appoints Medical Device Industry Veteran Brian Walsh as Chairman of the Board

  10/9/2018

  Walsh’s Commercial Expertise will Benefit Cagent’s Efforts to Develop Serranator Market

• Cagent Vascular Raises $11.87M to Fund the Growth and Expansion of the Serranator Family of Percutaneous Transluminal Angioplasty (PTA) Serration Balloon Catheters

  7/12/2018

  Cagent Vascular®announced the completion of $11.87 million in Series B funding.

• Cagent Vascular Presents Positive Results from the PRELUDE Study at LINC 2018

  2/7/2018

  Dr. Andrew Holden (Auckland, New Zealand), Principal Investigator, presented 30-day and preliminary 6-month results using the FDA 510(k) cleared Serranator Alto PTA Serration Balloon Catheter at the Leipzig Interventional Course last week.

• 

  Cagent Vascular Wins CE Mark for Serranator, a Next Generation Device for Vessel Dilatation in PA...

  11/20/2017

  The Serranator is one of a family of peripheral artery disease technologies which incorporates proprietary Serration Technology to an angioplasty balloon.

• Cagent Vascular Completes Enrollment Of PRELUDE Study Using Serranator Device

  6/6/2017

• FDA Green Lights Cagent Vascular's Next Generation Vessel Dilatation Device

  2/27/2017